Cationic amphiphilic drug-induced phospholipidosis

Toxicologic Pathology

Volumn 25, Issue 1, 1997, Pages 53-60

  Halliwell, William H ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

cationic amphiphilic drugs; foamy alveolar macrophages; lysosomal lamellar bodies; phospholipid storage disorder; Phospholipidosis

Indexed keywords

AMINE; AMPHOPHILE; ANOREXIGENIC AGENT; ANTIANGINA PECTORIS AGENT; ANTIARRHYTHMIC AGENT; ANTIDEPRESSANT AGENT; ANTIINFECTIVE AGENT; ANTIMALARIAL AGENT; CATION; HYPOCHOLESTEROLEMIC AGENT; NEUROLEPTIC AGENT; PHOSPHOLIPASE; PHOSPHOLIPID;

CONFERENCE PAPER; DRUG INDUCED DISEASE; HUMAN; LIPIDOSIS; LYSOSOME MEMBRANE; NONHUMAN; PHOSPHOLIPID METABOLISM; PRIORITY JOURNAL; RISK ASSESSMENT;

ANIMALIA; MAMMALIA;

EID: 0031057309     PISSN: 01926233     EISSN: None     Source Type: Journal    
DOI: 10.1177/019262339702500111     Document Type: Conference Paper

References (87)

1. Aubert-Tulkans G, VanHoof F, and Tulkens P (1979). Gentamicin-induced lysosomal phospholipidosis in cultured rat fibroblasts. Lab. Invest. 40: 481-491.
2. Beckett AH, Navas GE, and Hutt AJ (1988). Metabolism of chlorpromazine and promazine in vitro: Isolation and characterization of N-oxidation products. Xenobiotica 18: 61-74.
3. Blackmore PF (1988). Hormonal modulation of cytosolic free calcium. Am. J. Med. Sci. 296: 246-248.
4. Bloom BM and Laubach GD (1962). The relationship between chemical structure and pharmacological activity. Annu. Rev. Pharmacol. 2: 67-108.
5. Camus, P. (1989). Pathobiology of drug-induced lung disease. In: Treatment-Induced Respiratory Disorders, Vol. 3, GM Akoun, JP White, and MNG Dukes (eds). Elsevier, New York, pp. 24-46.
6. Camus P and Mehendale HM (1986) Pulmonary sequestration of amiodarone and desethylamiodarone. J. Pharmacol. Exp. Ther. 237: 867-873.
7. Cantor JO, Keller S, Mandl I, and Turino GM (1987). Increased synthesis of elastin in amiodarone-induced pulmonary fibrosis. J. Lab. Clin. Med. 109: 480-485.
8. Cantor JO, Osman M, Cerreta JM, Suarez R, Mandl I, and Turino GM (1984). Amiodarone-induced pulmonary fibrosis in hamsters. Exp. Lung Res. 6: 1-10.
9. +-ATPase activity in rat brain synaptic membranes. Biochem. Biophys. Res. Commun. 129: 148-154.
10. Chen GL, Sutrina SL, Frayer KL, and Chen WW (1986). Effects of lysosomotropic agents on lipogenesis. Arch. Biochem. Biophys. 245: 67-75.
11. Colbran RJ, Schworer C-M, Hashimoto Y, Fong Y-L, Rich DP, Smith MK, and Soderling TR (1989). Calcium/calmodulin-dependent protein kinase II. Biochem. J. 258: 313-325.
12. Cotran RS, Kumar V, and Robbins SL (1994). Genetic disorders. In: Robbins Pathologic Basis of Disease, 5th ed., RS Cotran, V Kumar, and SL Robbins (eds). W. B. Saunders Co., Philadelphia, PA, pp. 138-143.
13. DeDuve C, DeBarsy T, Poole B, Trouet A, Tulkens P, and Van Hoof F (1974). Lysosomotrophic agents. Pharmacology 23: 2495-2531.
14. Drew R, Siddik ZH, Mimnaugh EG, and Gram TE (1981). Species and dose differences in the accumulation of imipramine by mammalian lungs. Drug Metab. Dispos. 9: 322-326.
15. Farese RV (1988). Calcium as an intracellular mediator of hormone action: intracellular phospholipid signaling systems. Am. J. Med. Sci. 296: 223-270.
16. Feldman S, Wang M-Y, and Kaloyanides GJ (1982). Aminoglycosides induce a phospholipidosis in renal cortex of the rat: an early manifestation of nephrotoxicity. J. Pharmacol. Exp. Ther. 220: 514-520.
17. Gloster J, Heath D, Hasleton P, and Harris P (1976). Effect of chlorphentermine on the lipids of rat lungs. Thorax 31: 558-564.
18. Gordon M, Cook L, Tedeschi DH, and Tedeschi RE (1963). Some structure-activity relationships in the phenothiazines. Arzneim. Forsch. 13: 318-320.
19. Greselin E (1966). An inhibitor of cholesterol biosynthesis and the alveolar macrophages. Can. J. Comp. Med. Vet. Sci. 30: 121-126.
20. Heath MF, Costa-Jussa FR, Jacobs JM, and Jacobson W (1985). The induction of pulmonary phospholipidosis and the inhibition of lysosomal phospholipases by amiodarone. Br. J. Exp. Pathol. 66: 391-397.
21. Holt DW, Tucker GT, Jackson PR, and Storey GCA (1983). Amiodarone pharmacokinetics. Am. Heart J. 106: 840-847.
22. 1 of rat lung by amiodarone and desethylamiodarone. Biochim. Biophys. Acta. 959: 316-321.
23. Hosteller KY and Matsuzawa Y (1981). Studies on the mechanism of drug-induced lipidosis. Cationic amphiphilic drug inhibition of lysosomal phospholipases A and C. Biochem. Pharmacol. 30: 1121-1126.
24. Hosteller KY, Reasor MJ, Walker ER, Yazaki PJ, and Frazee BW (1986). Role of phospholipase A inhibition in amiodarone pulmonary toxicity in rats. Biochim. Biophys. Acta. 875: 400-405.
25. Hruban Z (1984). Pulmonary and generalized lysosomal storage induced by amphiphilic drugs. Environ. Health Perspect. 55: 53-76.
26. Hruban Z, Slesers A, and Aschenbrenner I (1973). Pulmonary intraalveolar histiocytosis induced by drugs. Toxicol. Appl. Pharmacol. 26: 72-85.
27. Hruban Z, Slesers A, and Hopkins E (1972). Drug-induced naturally occurring myeloid bodies. Lab. Invest. 27: 62-70.
28. Jeng AY, and Blumberg PM (1989). Biochemical mechanisms of action of the phorbol ester class of tumor promoters. In: The Pathobiology of Neoplasia, A. E. Sivica (ed). Plenum Press, New York, pp. 371-383.
29. Joshi UM, Kodavanti PRS, Coudert B, Dwyer TM, and Mehendale HM (1988). Types of interaction of amphiphilic drugs with phospholipid vesicles. J. Pharmacol. Exp. Ther. 246: 150-157.
30. Joshi UM, Rao P, Kodavanti S, Coudert B, Dwyer TM, and Mehendale HM (1988). Types of interaction of amphiphilic drugs with phospholipid vesicles. J. Pharmacol. Exp. Ther. 246: 150-157.
31. Joshi UM, Kodavanti PRS, Lockard VG, and Mehendale HM (1989). Fluorescence studies on binding of amphiphilic drugs to isolated lamellar bodies: relevance to phospholipidosis. Biochim. Biophys. Acta. 1004: 309-320.
32. Joshi UM, and Mehendale HM (1989). Drug-induced pulmonary phospholipidosis. Comm. Toxicol. 3: 91-115.
33. Kacew S (1984). Role of age in amphiphilic drug-induced pulmonary morphological and metabolic responses. Fed. Proc. 43: 2592-2596.
34. Kacew S (1985). Gentamicin or chlorphentermine induction of phospholipidoses in the developing organism: role of tissue and species in manifestation of toxicity. J. Pharmacol. Exp. Ther. 232: 239-243.
35. Kacew S (1987). Cationic amphiphilic drug-induced renal cortical lysosomal phospholipidosis: An in vivo comparative study with gentamicin and chlorphentermine. Toxicol. Appl. Pharmacol. 91: 469-476.
36. Kacew S, Nabraitz R, Ruddick JA, and Villeneuve DC (1981). Role of drug metabolism in protection against chlorphentermine-induced pulmonary phospholipidosis in adult rat. Exp. Mol. Pathol. 35: 98-107.
37. Kacew S and Reasor MJ (1983). Chlorphentermine-induced alterations in pulmonary phospholipid content in rats. Biochem. Pharmacol. 32: 2683-2688.
38. Kaczmarek LK (1988). The regulation of neuronal calcium and potassium channels by protein phosphorylation. In: Advances in Second Messenger and Phosphoprolein Research, Vol. 22, P Greengard and GA Robison (eds). Raven Press, New York, pp. 113-138.
39. Kodavanti UP and Mehendale HM (1990). Cationic amphiphilic drugs and phospholipid storage disorder. Pharm. Rev. 42: 327-353.
40. 14C-amiodarone uptake by perfused lung. Am. J. Respir. Cell Mol Biol. 4: 369-378.
41. Kubo M, Gardner MF, and Hosteller KY (1986). Binding of propranolol and gentamicin to small unilamellar phospholipid vesicles. Contribution of ionic and hydrophobic forces. Biochem. Pharmacol. 35: 3761-3765.
42. 1. Biochemistry 24: 6515-6520.
43. Lambert G, Lamontagne D, Hottlet H, and DuSouich P (1989). Amiodaronedigoxin interaction in rats: A reduction in hepatic uptake. Drug Metab. Dispos. 17: 704-708.
44. Lee AG (1978). Effects of charged drugs on the phase transition temperatures of phospholipid bilayers. Biochim. Biophys. Acta 514: 95-104.
45. Leli U and Hauser G (1987). Modifications of phospholipid metabolism induced by chlorpromazine, desmethylimipramine and propranolol in C6 glioma cells. Biochem. Pharmacol. 36: 31-37.
46. Levy JV and Richards V (1966). Inotropic and chronotropic effects of a series of β-adrenergic blocking drugs: Some structure-activity relationships. Proc. Soc. Exp. Biol. Med. 122: 373-379.
47. Lullmann H, Lullmann-Rauch R, and Wassermann O (1975). Drug-induced phospholipidosis. CRC Crit. Rev. Toxicol. 2: 185-218.
48. Lullmann H, Lullmann-Rauch R, and Wassermann O (1978). Lip idosis induced by amphiphilic cationic drugs. Biochem. Pharmacol. 27: 1103-1108.
49. Lullmann H and Wehling M (1979). The binding of drugs to different polar lipids in vitro. Biochem. Pharmacol. 28: 3409-3415.
50. Lullmann-Rauch R (1979). Drug-induced lysosomal storage disorder. In: Lysosomes in Applied Biology and Therapeutics. J. T. Dingle, P. J. Jacques, and I. H. Shaw (eds). North Holland Publishing Co., New York. pp. 49-130.
51. Lullmann-Rauch R and Reil G-H (1974). Chlorphentermine-induced lipidosis like ultrastructural alterations in lungs and adrenal glands of several species. Toxicol. Appl. Pharmacol. 30: 408-421.
52. Lullmann-Rauch R and Scheid D (1975). Intraalveolar form cells associated with lipidosis-like alterations in lung and liver of rats treated with tricyclic psychotropic drugs. Virchows Arch. B Cell Pathol. 19: 255-268.
53. Lullmann-Rauch R and Watermann D (1987). Fusion of storage lysosomes in experimental lipidosis and glycogenosis. Exp. Mol. Pathol 46: 136-143.
54. Martin WJ II, Kachel DL, Vilen T, and Natarajan V (1989). Mechanism of phospholipidosis in amiodarone pulmonary toxicity. J. Pharmacol. Exp. Ther. 251: 272-278.
55. Mason JW, Hondeghem LM, and Katzung BG (1984). Block of inactivated sodium channels and of depolarization-induced automaticity in guinea pig papillary muscle by amiodarone. Circ. Res. 55: 277-285.
56. McCloud CM, Kacew S, Beard T, Ebert D, and Reasor MJ (1995). Drug accumulation and induction of alveolar macrophage phospholipidosis after amiodarone treatment in two strains of rats. Toxicologist 15: 196.
57. 2+-ATPase activities and shape change of erythrocyte ghosts by chloroquine. Biochem. Pharmacol. 36: 3433-3437.
58. Nishizuka Y (1984). The role of protein kinase C in cell surface signal transduction and tumor promotion. Nature (Lond.) 308: 693-698.
59. Opstvedt A, Rongved S, Aarsaether N, Lillehaug JR, and Holmsen H (1986). Differential effects of chlorpromazine on secretion, protein phosphorylation and phosphoinositide metabolism in stimulated platelets. Biochem. J. 238: 159-166.
60. Patil PN (1968). Steric aspects of adrenergic drugs. VIII. Optical isomers of β-adrenergic receptor antagonists. J. Pharmacol. Exp. Ther. 160: 308-314.
61. Philpot RM, Anderson MW, and Eling TE (1977). Uptake, accumulation and metabolism of chemicals by the lung. In: Metabolic Functions of the Lung, Vol. 4. YS Bakhle and JR Vane (eds). Dekker, Inc., New York, pp. 123-171.
62. Pirovino M, Muller O, Zysset T and Honegger U (1988). Amiodarone-induced hepatic phospholipidosis: Correlation of morphological and biochemical findings in an animal model. Hepatology 8: 591-598.
63. 2+ associated with cellular injury to human pulmonary artery endothelial cells. Toxicol. Appl. Pharmacol. 103: 156-164.
64. Reasor MJ (1989). A review of the biology and toxicologic implications of the induction of lysosomal lamellar bodies by drugs. Toxicol. Appl. Pharmacol. 97: 47-56.
65. Reasor MJ (1984). Phospholipidosis in the alveolar macrophage induced by cationic amphophilic drugs. Fed. Proc. 43: 2578-2581.
66. Reasor MJ and Keyneman CA (1983). Disaturated phosphatidylcholine in the pulmonary air spaces of rats treated with chlorphentermine. Biochem. Pharmacol. 32: 939-941.
67. Riva E, Marchi S, Presenti A, Bizzi A, Cini M, Veneroni E, Tavbani E, Boeri R, Bertani T and Latini R (1987). Amiodarone induced phospholipidosis biochemical, morphological, and functional changes in the lungs of rats chronically treated with amiodarone. Biochem. Pharm. 36: 3209-3214.
68. Ruben Z (1987). The pathobiologic significance of intracellular drug storage: Clear cytoplasmic vacuoles. Hum. Pathol. 18: 1197-1198.
69. Ruben Z, Anderson SN, Rorig KJ, Hribar JD, and Bible RH Jr (1985). The pH dependence of disobutamide-induced clear cytoplasmic vacuoles in cultured cells (42147). Proc. Soc. Exp. Biol. Med. 180: 84-91.
70. Ruben Z, Dodd DC, Rorig KJ, and Anderson SN (1989). Disobutamide: a model agent for investigating intracellular drug storage. Toxicol. Appl. Pharmacol. 97: 57-71.
71. Sauers LJ, Wierda D, and Reasor MJ (1988). Chlorphentermine suppresses the phospatidylinositol pathway in concanavalin A-activated mouse splenic lymphocytes. Immunopharmacol. Immunotoxicol. 10: 1-19.
72. Sauers LJ, Wierda D, Walker ER, and Reasor MJ (1986). Morphological and functional changes in mouse splenic lymphocytes following in vivo and in vitro exposure to chlorphentermine. J. Immunopharmacol. 8: 611-631.
73. Seeman P (1977). Anti-schizophrenic drugs - Membrane receptor sites of action. Biochem. Pharmacol. 26: 1741-1748.
74. Seeman P, Staiman A, and Chau-Wong M (1974). The nerve impulse-blocking actions of tranquilizers and the binding of neuroleptics to synaptosome membranes. J. Pharmacol. Exp. Ther. 190: 123-130.
75. Seydel U, Brandenburg K, Lindner B, and Moll H (1981). The influence of phospholipidosis inducing drugs on phase transition of lipids. Thermochim. Acta 49: 35-48.
76. Seydel JK and Wassermann O (1976). NMR-studies on the molecular bases of drug-induced phospholipidosis. II. Interaction between several amphiphilic drugs and phospholipids. Biochem. Pharmacol. 25: 2357-2364.
77. Shaikh NA, Downar E, and Butany J (1987). Amiodarone - An inhibitor of phospholipase activity: A comparative study of the inhibitory effects of amiodarone, chloroquine and chlorpromazine. Mol. Cell. Biochem. 76: 163-172.
78. Shikata T, Kanetaka T, Endo Y, and Nagashima K (1972). Drug-induced generalized phospholipidosis. Acta Pathol. Jpn. 22: 517-531.
79. Smith P, Heath D, and Hasleton PS (1973). Electron microscopy of chlorphentermine lung. Thorax 28: 559-566.
80. Svendsen O (1977). The effect of phenobarbital on chlorphentermine-induced alveolar foam cells in rats. Toxicol. Appl. Pharmacol. 40: 171-173.
81. 2+ pump ATP-ase by cAMP-dependent phosphorylation of phospholamban. Biol. Essays 10: 157-163.
82. Taylor SS (1989). cAMP-dependent protein kinase. Model for an enzyme family. J. Biol. Chem. 264: 8443-8446.
83. 1. J. Cell Biol. 63:430-440.
84. Wilmotte E, Maldague P, Tulkens R Baumgartner R, Schmook F, Walz H, and Obenaus H (1983). S86451, a new derivative of gentamicin with reduced nephrotoxicity. Biochemical, morphological and functional studies. Drug Exp. Clin. Res. 9: 467-477.
85. Yamamoto A, Adachi S, Kitani T, Shinji Y, Seki K, Nasu T, and Nishikawa M (1971). Drug-induced lipidosis in human cases and in animal experiments. J. Biochem. (Tokyo) 69: 613-615.
86. Yap SH, Rijntjes PJM, Moshage HJ, Croes H, and Jap PHK (1987). Amiodarone-induced lysosomal inclusions in primary cultures of human hepatocytes. Gastroenterology 92: 272-273.
87. Zychlinski L and Montgomery MR (1985). Chlorphentermine-induced biochemical alterations in mitochondrial membranes. J. Pharmacol. Exp. Ther. 233: 39-44.